COMING SOON: EV-302/KEYNOTE-A39: Open-Label, Randomized Phas

COMING SOON: EV-302/KEYNOTE-A39: Open-Label, Randomized Phase 3 Study of Enfortumab Vedotin in Combination with Pembrolizumab vs Chemotherapy in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma

Terence Friedlander, MD, shares a look at an upcoming program reviewing recent, significant data from the EV-302/KEYNOTE-A39 study.

Related Keywords

Enfortumab Vedotin , , Randomized Phase , Previously Untreated Locally Advanced , Metastatic Urothelial , Urothelial Carcinoma , Urothelial Cancer , Advanced Or Metastatic Urothelial Carcinoma , Ev 302 , Keynote A39 ,